NS-2710 (LS-193,970) is an
anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company
NeuroSearch. It has similar effects to
benzodiazepine drugs, but is structurally distinct and so is classed as a
nonbenzodiazepine anxiolytic. NS-2710 is a potent but non-selective
partial agonist at
GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has
anxiolytic effects comparable to
chlordiazepoxide,[1] and while it is a less potent
anticonvulsant than the related drug
NS-2664, it has a much longer duration of action, and similarly to other α2/α3-preferring partial agonists produces little
sedative effects or physical dependence.[2]
References
^Evenden J, Duncan B, Ko T (February 2006). "A comparison of the effects of psychotomimetics and anxiolytics on punished and unpunished responding maintained by fixed interval schedules of food reinforcement in the rat". Behavioural Pharmacology. 17 (1): 87–99.
doi:
10.1097/01.fbp.0000189812.77049.e5.
PMID16377966.
S2CID12424100.
^Mirza NR, Nielsen EØ (March 2006). "Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?". The Journal of Pharmacology and Experimental Therapeutics. 316 (3): 1378–85.
doi:
10.1124/jpet.105.094474.
PMID16352707.
S2CID22700422.